Thymosin beta 4 ( DrugBank: Thymosin beta 4 )
2 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
36 | Epidermolysis bullosa | 1 |
53 | Sjogren syndrome | 1 |
36. Epidermolysis bullosa
Clinical trials : 160 / Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00311766 (ClinicalTrials.gov) | February 2006 | 4/4/2006 | A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa | A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Epidermolysis Bullosa | Epidermolysis Bullosa | Drug: Thymosin Beta 4;Drug: Placebo | RegeneRx Biopharmaceuticals, Inc. | NULL | Terminated | 2 Years | N/A | All | 30 | Phase 2 | United States |
53. Sjogren syndrome
Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01393132 (ClinicalTrials.gov) | March 2011 | 7/7/2011 | Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye | Comparative Study of Thymosin Beta 4 Eye Drops or Vehicle in the Treatment of Patients With Ocular Surface Defects Due to Severe Dry Eye | Dry Eye;Sjogren's Syndrome;Graft vs. Host Disease | Drug: Thymosin Beta 4 eye drops;Drug: Vehicle Control | Michigan Cornea Consultants, PC | Kresge Eye Institute | Completed | 18 Years | 90 Years | All | 9 | Phase 2 | United States |